HPV infections in head and neck cancers (HNSCC) – clinical course and efficiency of therapy

1. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insgiht 2016;1(17):e89829.10.1172/jci.insight.89829507096227777979Search in Google Scholar

2. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10(11):3755-62.10.1158/1078-0432.CCR-04-005415173082Search in Google Scholar

3. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005;24(1):95-105.10.1007/s10555-005-5050-615785875Search in Google Scholar

4. López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006;176(6):3402-9.10.4049/jimmunol.176.6.340216517708Search in Google Scholar

5. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013;49(12):1089-96.10.1016/j.oraloncology.2013.09.009486114724126223Search in Google Scholar

6. Payne MJ, Argyropoulou K, Lorigan P, McAleer JJ, Farrugia D, Davidson N, et al. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 2014;32(3):185-90.10.1200/JCO.2013.49.871724344211Search in Google Scholar

7. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22):6681-8.10.1158/1078-0432.CCR-07-0187214708317982122Search in Google Scholar

8. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108.10.3322/caac.2126225651787Search in Google Scholar

9. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15(9):994-1001.10.1634/theoncologist.2009-0289322803920798198Search in Google Scholar

10. Kim L, King T, Agulnik M. Head and neck cancer: changing epidemiology and public health implications. Oncology (Williston Park) 2010;24(10):915-9.Search in Google Scholar

11. Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget 2014;5(12):3956-69.10.18632/oncotarget.1934414729824970795Search in Google Scholar

12. Lajer CB, von Buchwald C. The role of human papillomavirus in head and neck cancer. APMIS 2010;118(6-7):510-9.10.1111/j.1600-0463.2010.02624.x20553531Search in Google Scholar

13. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108(5):766-72.10.1002/ijc.1163314696105Search in Google Scholar

14. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt B):1-441.Search in Google Scholar

15. Michaud DS, Langevin SM, Eliot M, Nelson HH, Pawlita M, McClean MD, et al. High-risk HPV types and head and neck cancer. Int J Cancer 2014;135(7):1653-61.10.1002/ijc.28811410708224615247Search in Google Scholar

16. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24(5):736-47.10.1200/JCO.2004.00.333516401683Search in Google Scholar

17. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100(4):261-9.10.1093/jnci/djn01118270337Search in Google Scholar

18. Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence 2015;6(3):244-8.10.1080/21505594.2014.999570460123825654476Search in Google Scholar

19. Spangle JM, Munger K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PLoS Pathog 2013;9(3): e1003237.10.1371/journal.ppat.1003237359753323516367Search in Google Scholar

20. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 2008;112(12):2710-9.10.1002/cncr.2344218481809Search in Google Scholar

21. RTOG. RTOG 1016 Phase III Trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. 2013.Search in Google Scholar

22. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Anti-tumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34(32):3838-45.10.1200/JCO.2016.68.1478680489627646946Search in Google Scholar

23. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375(19):1856-67.10.1056/NEJMoa1602252556429227718784Search in Google Scholar

24. Ferris RL, Gonçalves A, Baxi SS, Martens UM, Gauthier H, Langenberg M, et al. LBA46: An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2017;28 Suppl 5:605-49.10.1093/annonc/mdx440.041Search in Google Scholar

25. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128(4):927-35.10.1002/ijc.25396Search in Google Scholar

26. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11(11):1048-56.10.1016/S1470-2045(10)70230-8Search in Google Scholar

27. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):89-99.10.1016/S1470-2045(11)70286-8Search in Google Scholar

28. Villa LL, Perez G, Kjaer SK, Paavonen J, Lehtinen M, Muñoz N, et al. Quad-rivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med 2007;356:1915-27.10.1056/NEJMoa06174117494925Search in Google Scholar

29. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec 2017;92(19):241-68.Search in Google Scholar

30. Leung TF, Liu AP, Lim FS, Thollot F, Oh HML, Lee BW, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14 years: Results to month 36 from a randomized trial. Vaccine 2018;36(1):98-106.10.1016/j.vaccine.2017.11.03429174109Search in Google Scholar

31. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011;105(1):28-37.10.1038/bjc.2011.185313740321629249Search in Google Scholar

32. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14(2):467-75.10.1158/1055-9965.EPI-04-055115734974Search in Google Scholar

33. Macedo R, Rochefort J, Guillot-Delost M, Tanaka K, Le Moignic A, Noizat C, et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles. Oncoimmunology 2016;5(7):e1164363.10.1080/2162402X.2016.1164363500690227622018Search in Google Scholar

34. Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 2013;12(3):271-83.10.1586/erv.13.2323496667Search in Google Scholar

35. Adams AK, Wise-Draper TM, Wells SI. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers (Basel) 2014;6(3):1793-820.10.3390/cancers6031793419056825226287Search in Google Scholar

36. Whang SN, Filippova M, Duerksen-Hughes P. Recent progress in therapeutic treatments and screening strategies for the prevention and treatment of HPV-associated head and neck cancer. Viruses 2015;7(9):5040-65.10.3390/v7092860458430426393639Search in Google Scholar

37. Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, et al. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. Ann Oncol 2017;28(9):2213-8.-10.1093/annonc/mdx32028651338Search in Google Scholar